GlassScriptPhysician profile
Fayaz A Faiz
NPI 1467498642
$1,822.64
in general payments reported to CMS, 2019-2025
28 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $47.47 · 2021: $240 · 2022: $218 · 2023: $380 · 2024: $442 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $227.58 | 2022-2025 | |
| Abbvie INC. | $199.20 | 2021-2025 | |
| Genentech USA, INC. | $147.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $139.50 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $122.04 | 2021-2022 | |
| Eisai INC. | $107.44 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $88.07 | 2023-2025 | Rytary, Crexont |
| Ucb, INC. | $86.52 | 2019-2021 | |
| Ge Healthcare | $76.87 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $65.24 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $58.62 | 2021-2024 | Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $52.87 | 2019 | |
| Allergan, INC. | $47.47 | 2020 | |
| Emd Serono, INC. | $45.26 | 2022-2023 | Mavenclad |
| Medtronic USA, INC. | $43.13 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $40.87 | 2021-2024 | Skyclarys |
| Lundbeck LLC | $38.61 | 2023 | Rexulti |
| Avion Pharmaceuticals | $34.74 | 2022 | |
| Neurelis, INC. | $33.28 | 2021-2022 | |
| Argenx US, INC. | $25.18 | 2023 | Vyvgart |
| Aprecia Pharmaceuticals, LLC | $22.65 | 2019 | |
| Acadia Pharmaceuticals INC | $21.57 | 2022 | |
| Banner Life Sciences, LLC | $21.17 | 2022 | |
| Livanova USA, INC. | $16.99 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genzyme Corporation | $16.08 | 2022 | |
| Aucta Pharmaceuticals, INC. | $15.93 | 2024-2025 | Motpoly Xr |
| Biohaven Pharmaceuticals, INC. | $14.79 | 2021 | |
| Insightec,INC | $13.66 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fayaz Faiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.